BMRN Stock Latest News

BioMarin assumed with an Overweight at Barclays

PremiumThe Fly

3d ago

BioMarin Announces Major Debt Financing for Amicus Acquisition

PremiumCompany Announcements

4d ago

BioMarin upgraded to Buy from Hold at Canaccord

PremiumThe Fly

10d ago

BioMarin: Undervalued Growth Story Reinforced by Strategic Amicus Acquisition and Expanding Rare-Disease Franchise

PremiumRatings

10d ago

PremiumCompany AnnouncementsBioMarin’s Palynziq Pregnancy Study: What the Latest Update Means for Investors

15d ago

BioMarin Deepens Long-Term Palynziq Data With New PKU Post‑Marketing Study

Company Announcements

BioMarin Deepens Long-Term Palynziq Data With New PKU Post‑Marketing Study

15d ago

BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors

Company Announcements

BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors

15d ago

BioMarin: Sustained Double-Digit Growth Story Underpinned by Voxzogo Leadership, Advancing Rare-Disease Pipeline, and Accretive Amicus Acquisition

PremiumRatings

17d ago

Balanced View on BioMarin: Solid Near-Term Guidance Offset by Voxzogo Competitive Risks and Roctavian Challenges, Supporting a Hold Rating

PremiumRatings

17d ago

BioMarin: Buy Rating Reaffirmed on Strong 2025 Outlook, Promising Pipeline, and Accretive M&A

PremiumRatings

18d ago

Closing Bell Movers: Revvity up 9% on strong outlook

PremiumThe Fly

18d ago

DAL

PremiumThe FlyBioMarin sees FY25 revenue $3.2B, consensus $3.17B

18d ago

BioMarin names Arpit Dave Chief Digital and Information Officer

The Fly

BioMarin names Arpit Dave Chief Digital and Information Officer

18d ago

AMGN

Veeva, BioMarin announce long-term enterprise agreement

The Fly

Veeva, BioMarin announce long-term enterprise agreement

22d ago

BioMarin price target raised to $100 from $80 at Truist

VEEV

PremiumThe Fly

1M ago

Spruce Biosciences initiated with an Outperform at Oppenheimer

PremiumThe Fly

1M ago

BioMarin Ends Development of BMN 349 AATD Therapy

SPRB

PremiumCompany Announcements

1M ago

BofA moves to No Rating on Amicus after BioMarin deal

PremiumThe Fly

1M ago

PremiumThe FlyBioMarin price target raised to $60 from $55 at H.C. Wainwright

1M ago

William Blair views BioMarin acquisition of Amicus as ‘strategic fit’

The Fly

William Blair views BioMarin acquisition of Amicus as ‘strategic fit’

1M ago

Balanced View on BioMarin’s Amicus Acquisition: Strategic Rare-Disease Upside Versus Near-Term Leverage and Earnings Dilution Supports Hold Rating

Ratings

Balanced View on BioMarin’s Amicus Acquisition: Strategic Rare-Disease Upside Versus Near-Term Leverage and Earnings Dilution Supports Hold Rating

1M ago